|
Abbott and Dexcom Settle Global Patent Disputes Over CGM Technologies
|
Written by: J. Smith |
Hits: 954
|
|
Novo Nordisk’s CagriSema Falls Short of Investor Expectations Despite Promising Weight-Loss Results
|
Written by: J. Smith |
Hits: 583
|
|
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
|
Written by: J. Smith |
Hits: 653
|
|
Possible Link Between Semaglutide and Vision Loss Raises Questions
|
Written by: J. Smith |
Hits: 716
|
|
Dexcom Launches First Generative AI Platform in Glucose Biosensing
|
Written by: J. Smith |
Hits: 534
|
|
Eli Lilly and Novo Nordisk Ramp Up GLP-1 Manufacturing Capacity
|
Written by: J. Smith |
Hits: 1176
|
|
Novo Nordisk to Slash US Insulin Prices in 2026
|
Written by: J. Smith |
Hits: 980
|
|
Eli Lilly’s Zepbound Outperforms Novo Nordisk’s Wegovy in Head-to-Head Weight Loss Study
|
Written by: J. Smith |
Hits: 601
|
|
Exploring CGM Data
|
Written by: J. Smith |
Hits: 560
|
|
Dexcom and Oura: A Strategic Partnership to Revolutionize Metabolic Health Tracking
|
Written by: J. Smith |
Hits: 766
|
